Lin Ruiting, Chen Ruilian, Chen Zhiqiang, Hu Leihao, Guo Wei, Zhang Zexin, Lin Lizhu, Chen Hanrui
First Clinical Medical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
Department of Oncology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
Front Oncol. 2021 Sep 2;11:731572. doi: 10.3389/fonc.2021.731572. eCollection 2021.
The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations. Here, we report the case of a 68-year-old man with advanced NSCLC with concurrent EGFR L861Q mutation as well as TP53 and RB1 mutations. The patient was treated with osimertinib as first-line therapy and achieved a remarkable progression-free survival of 15 months. His symptoms were significantly alleviated and the dose was well tolerated. The findings of the present study indicate that osimertinib might be a good treatment option for NSCLC patients with the L861Q mutation.
第一代和第二代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在伴有EGFR L861Q突变的非小细胞肺癌（NSCLC）患者中的疗效此前已得到研究。然而，关于奥希替尼在伴有罕见突变的NSCLC患者中的疗效，几乎没有证据。在此，我们报告一例68岁患有晚期NSCLC的男性病例，该患者同时存在EGFR L861Q突变以及TP53和RB1突变。该患者接受奥希替尼作为一线治疗，无进展生存期达15个月，效果显著。其症状明显缓解，且对该剂量耐受性良好。本研究结果表明，奥希替尼可能是伴有L861Q突变的NSCLC患者的一个良好治疗选择。
